(READ) ‘Uniquely complicated course’ for patient treated with controversial new Alzheimer’s drug: aducanumab

The following is an excerpt from Medpage Today. A man treated with the recently approved Alzheimer’s drug aducanumab (Aduhelm) had six amyloid-related imaging abnormality (ARIA) episodes, researchers reported. Over 44 months in a long-term extension study, the Alzheimer’s disease patient had recurrent episodes of asymptomatic mild or moderate ARIA-edema (ARIA-E), with one episode including mild […]

Share DeepPol